Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. The company is headquartered in Tarrytown, New York and currently employs 15,410 full-time employees.  The firm invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. The firm is accelerating drug development using its proprietary technologies, such as VelociSuite, which produces optimized fully human antibodies and new classes of bispecific antibodies. VelociSuite consists of VelocImmune, VelociGene, VelociMouse, VelociMab, Veloci-Bi, VelociT, VelociHum, and other related technologies. Its marketed products include EYLEA (aflibercept); Dupixent (dupilumab); Libtayo (cemiplimab); Ordspono (odronextamab); Kevzara (sarilumab); Itepekimab; Lynozyfic, and others.

Regeneron Pharmaceuticals, Inc. adalah perusahaan bioteknologi yang terlibat dalam penemuan, invensi, pengembangan, manufaktur, dan komersialisasi obat-obatan. Perusahaan ini berkantor pusat di Tarrytown, New York dan saat ini mempekerjakan 15.410 karyawan penuh waktu. Perusahaan ini menciptakan, mengembangkan, memproduksi, dan mengkomersialkan obat-obatan untuk orang-orang dengan penyakit serius. Produk dan kandidat produk yang sedang dikembangkan dirancang untuk membantu pasien dengan penyakit mata, penyakit alergi dan inflamasi, kanker, penyakit kardiovaskular dan metabolik, penyakit neurologis, kondisi hematologis, penyakit menular, dan penyakit langka. Perusahaan ini mempercepat pengembangan obat dengan menggunakan teknologi kepemilikannya, seperti VelociSuite, yang memproduksi antibodi manusia penuh yang dioptimalkan dan kelas baru antibodi bispesifik. VelociSuite terdiri dari VelocImmune, VelociGene, VelociMouse, VelociMab, Veloci-Bi, VelociT, VelociHum, dan teknologi terkait lainnya. Produk yang sudah dipasarkan mencakup EYLEA (aflibercept); Dupixent (dupilumab); Libtayo (cemiplimab); Ordspono (odronextamab); Kevzara (sarilumab); Itepekimab; Lynozyfic, dan lainnya.

Regeneron

NVIDIA

Apple

Google

Microsoft

Amazon

Taiwan Semiconductor

Broadcom

Meta Platforms

Tesla

Eli Lilly

Berkshire Hathaway

Micron Technology

Walmart

JPMorgan

ASML

Visa

Oracle

Exxon Mobil

Johnson & Johnson

Intel

Cisco

MasterCard

Costco

SPDR S&P500 ETF

Caterpillar

AbbVie

Bank of America

Lam Research

Chevron

UnitedHealth Group

Applied Materials

Netflix

General Electric

Coca-Cola

Procter & Gamble

Morgan Stanley

Palantir

Home Depot

Goldman Sachs

Vanguard Total Stock Market ETF

Merck

Alibaba

Novartis

AstraZeneca

Philip Morris

Royal Bank of Canada

Texas Instruments

Dell

Raytheon Technologies

Shell

Wells Fargo

Linde PLC

Marvell Technology

QUALCOMM

Citigroup

Palo Alto Networks

American Express

Toyota

Invesco QQQ Trust

McDonald's

TotalEnergies

Analog Devices

Novo Nordisk

Arista Networks

PepsiCo

T-Mobile

Seagate Technology

Amgen

Verizon

Toronto-Dominion Bank

Western Digital

NextEra Energy

Banco Santander

Disney

CrowdStrike

Boeing

BlackRock

Gilead Sciences

Abbott

AT&T

Deere

Union Pacific

Charles Schwab

Anheuser-Busch Inbev

Corning

Salesforce

Intuitive Surgical

Pfizer

Southern Copper

Uber

ConocoPhillips

Shopify

Blackstone

Prologis

Regeneron Stock

About Regeneron

Key Statistics

Insights

People Also Bought